- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
- Yale UrologyOrchard Medical Center at St. Raphael’s Campus330 Orchard Street, Ste Suite 164New Haven, CT 06511
- Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830
Isaac Y. Kim, MD, PhD, MBA
Biography
Isaac Yi Kim, MD, PhD, MBA, chair of the Department of Urology at Yale School of Medicine, specializes in the treatment and management of prostate cancer with the goal of helping patients navigate and better understand their disease. Although he cares for all men with localized disease, his clinical and research focus is in men with high-risk disease, recurrence after radiation, and metastatic prostate cancer to lymph nodes, bones, lungs, and abdominal organs.
Dr. Kim is an expert in minimally invasive robotic surgery and has performed more than 2,100 robot-assisted radical prostatectomies, which are surgeries to remove the entire prostate gland. In addition, he has established a same-day radical prostatectomy program by using the latest-generation da Vinci robot to remove a diseased prostate through a single, one-inch incision in the abdomen. This results in less pain—and pain medication—for the patient, who usually goes home the same day of the surgery.
He was inspired to become a prostate surgeon during his medical training, when he decided he wanted to help men he saw struggling with complications such as impotence and incontinence, which often develop after prostate cancer surgery. Those post-surgery problems are less common with expert robotic surgeons, he says. “I see what an impact and a difference the surgical robot has made in helping our patients and allaying their fears.”
As a professor at Yale School of Medicine, Dr. Kim is also a surgeon-scientist who is studying the mechanism of prostate cancer treatment resistance. He is the principal investigator in clinical trials focused on advanced and metastatic prostate cancer, providing surgery in men with Stage IV prostate cancer. He says the traditional paradigm shows that when cancer cells have escaped the organ of origin, it’s too late to help. But his early data is showing that removing the prostate may enhance the effectiveness of chemotherapy and hormonal therapies for men with late-stage disease.
Dr. Kim says working at Yale Medicine is rewarding because of the rich history and tradition that values innovation and creativity, and he is focused on providing the latest treatments for men who have any stage of prostate cancer. “Yale Urology is one of the larger departments in the nation and we attract patients from regions far beyond New Haven. We’re really dedicated to delivering the most innovative care in the most compassionate manner,” he says. “When a patient and concerned family members come in with a prostate cancer diagnosis, and I’m able to take care of it and see how he recovers, it is truly a privilege and a blessing.”
Titles
- Professor of Urology
- Chair, Urology
- Chief, Urology
- Co-Leader, Cancer Signaling Networks, Yale Cancer Center
Education & Training
- MBAUniversity of Pennsylvania Wharton Business School, Finance (2017)
- Research FellowshipNational Institutes of Health (2005)
- Clinical FellowshipUniversity of California, Irvine (2005)
- ResidentBaylor College of Medicine (2003)
- MDNorthwestern University, Feinberg School of Medicine (1997)
- PhDNorthwestern University Graduate School, Tumor Cell Biology (1996)
Additional Information
- AB of Urology, Urology (2007)
- Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K, Tuiche M, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott J, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir S, Mitrofanova A. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications 2024, 15: 352. PMID: 38191557, PMCID: PMC10774320, DOI: 10.1038/s41467-024-44686-5.
- Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.
- Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries. Frontiers In Urology 2023, 2: 1069265. DOI: 10.3389/fruro.2022.1069265.
- Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.
- Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.
- Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.
- Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome. Analyst 2022, 147: 3043-3054. PMID: 35642979, DOI: 10.1039/d2an00676f.
- Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.
- Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.
- Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Patel H, Sterling J, Srivastava A, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC). Journal Of The American College Of Surgeons 2021, 233: e230-e231. DOI: 10.1016/j.jamcollsurg.2021.08.623.
- Chua K, Mikail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of The American College Of Surgeons 2021, 233: s310-s311. DOI: 10.1016/j.jamcollsurg.2021.07.643.
- Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.
- Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.
- Chua K, Mikhail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of Urology 2021, 207: 684-691. PMID: 34694164, DOI: 10.1097/ju.0000000000002258.
- Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.
- Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 146-146. DOI: 10.1200/jco.2020.39.28_suppl.146.
- Sterling J, Kim I. EDITORIAL COMMENT. Urology 2021, 155: 151. PMID: 34488998, DOI: 10.1016/j.urology.2021.01.065.
- Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.
- Piao X, Hwang B, Jeong P, Byun Y, Kang H, Seo S, Kim W, Lee J, Ha Y, Lee Y, Kim I, Choi Y, Cha E, Moon S, Yun S, Kim W. Collagen type VI-α1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal Of Oncology 2021, 59: 37. PMID: 33982770, DOI: 10.3892/ijo.2021.5217.
- Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.
- Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.
- Mikhail M, Chua K, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. Journal Of Clinical Oncology 2021, 39: 357-357. DOI: 10.1200/jco.2021.39.6_suppl.357.
- Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.
- Srivastava A, Patel H, Kim S, Shinder B, Sterling J, Tabakin A, Polotti C, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Patel H, Jang T, Singer E. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Journal Of Clinical Oncology 2021, 39: 283-283. DOI: 10.1200/jco.2021.39.6_suppl.283.
- Manne S, Kashy D, Myers‐Virtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer. European Journal Of Cancer Care 2021, 30: e13401. PMID: 33586282, PMCID: PMC9165020, DOI: 10.1111/ecc.13401.
- Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.
- Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.
- Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.
- Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.
- Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.
- Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis. Journal Of Biophotonics 2020, 14: e202000275. PMID: 32909380, DOI: 10.1002/jbio.202000275.
- Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.
- Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.
- Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.
- Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.
- Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.
- Sterling J, Jang T, Kim I. EDITORIAL COMMENT. Urology 2020, 135: 122. PMID: 31895674, DOI: 10.1016/j.urology.2019.07.052.
- Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.
- Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.
- Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.
- Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.
- Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.
- Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.
- Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. PMID: 31139700, PMCID: PMC6526358.
- Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.
- Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556802.43534.0b.
- Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555316.15591.47.
- Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.
- Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial. British Journal Of Health Psychology 2019, 24: 396-418. PMID: 30852854, PMCID: PMC8279429, DOI: 10.1111/bjhp.12359.
- Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. DOI: 10.1200/jco.2019.37.7_suppl.672.
- Sterling J, Rivera-Nunez Z, Farber N, Modi P, Radadia K, Kim S, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses. Journal Of Clinical Oncology 2019, 37: 648-648. DOI: 10.1200/jco.2019.37.7_suppl.648.
- Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.
- Faiena I, Kim I, Jang T. Multimodal treatments for advanced prostate cancer. Oncotarget 2019, 10: 255-256. PMID: 30719221, PMCID: PMC6349456, DOI: 10.18632/oncotarget.26525.
- Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.
- Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.
- Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.
- Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.
- Manne S, Kashy D, Zaider T, Lee D, Kim I, Heckman C, Penedo F, Kissane D, Virtue S. Interpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners. Journal Of Family Psychology 2018, 32: 664-675. PMID: 29771551, PMCID: PMC6072581, DOI: 10.1037/fam0000404.
- Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 PMID: 30714046, PMCID: PMC6358174.
- Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget 2018, 9: 21359-21365. PMID: 29765545, PMCID: PMC5940363, DOI: 10.18632/oncotarget.25103.
- Ahlering T, Huynh L, Kamaljot K, Williams S, Osann K, Joseph J, Lee D, Lee D, Davis J, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. MP82-08 UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING. Journal Of Urology 2018, 199: e1108-e1109. DOI: 10.1016/j.juro.2018.02.2736.
- Diefenbach M, Hudson S, Marziliano A, Fleszar S, Tagai E, Bator A, Chen D, Cox B, Hall S, Kim I, Kim S, Kutikov A, Miyamoto C, Potters L, Reese A, Vira M, Torre G, DeCoster C, Bhat R, Hui S, Miller S. PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS. Journal Of Urology 2018, 199: e570. DOI: 10.1016/j.juro.2018.02.1382.
- Farber N, Rivera-Nunez Z, Kim S, Radadia K, Modi P, Goyal S, Parikh R, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: A PROPENSITY SCORE-WEIGHTED ANALYSIS. Journal Of Urology 2018, 199: e456. DOI: 10.1016/j.juro.2018.02.1135.
- Tabakin A, Kim S, Polotti C, Rivera-Núñez Z, Sterling J, Modi P, Farber N, Radadia K, Parikh R, Goyal S, Weiss R, Kim I, Elsamra S, Singer E, Jang T. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014. Journal Of Urology 2018, 199: e1129. DOI: 10.1016/j.juro.2018.02.2780.
- Ahlering T, Huynh L, Kaler K, Williams S, Osann K, Joseph J, Lee D, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. 269 Unintended consequences of decreased PSA-based prostate cancer screening. European Urology Open Science 2018, 17: e376-e377. DOI: 10.1016/s1569-9056(18)31114-x.
- Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.
- Kim W, Kim Y, Jeong P, Seo S, Kang H, Kim Y, Yun S, Lee S, Moon S, Choi Y, Lee G, Kim I, Kim W. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget 2018, 9: 14354-14365. PMID: 29581849, PMCID: PMC5865675, DOI: 10.18632/oncotarget.24436.
- Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M. The American Journal Of Chinese Medicine 2018, 46: 689-705. PMID: 29595070, DOI: 10.1142/s0192415x18500362.
- Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 2017, 5: 109783-109790. PMID: 29312648, PMCID: PMC5752561, DOI: 10.18632/oncotarget.21297.
- Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer. International Journal Of Surgery Oncology 2017, 2: e13. PMID: 29177226, PMCID: PMC5673152, DOI: 10.1097/ij9.0000000000000013.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2017, 4637-4640. DOI: 10.1007/978-3-662-46875-3_5930.
- Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis. International Journal Of Oncology 2017, 51: 204-212. PMID: 28498422, DOI: 10.3892/ijo.2017.3993.
- Parikh R, Kim I. Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Journal Of Clinical Oncology 2017, 35: jco.2017.72.484. PMID: 28471706, DOI: 10.1200/jco.2017.72.4849.
- Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Ahn H, Kim W, Singer E, Kim I. MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS IN RENAL CELL CARCINOMA. Journal Of Urology 2017, 197: e792-e793. DOI: 10.1016/j.juro.2017.02.1845.
- Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal Of Urology 2017, 197: e765. DOI: 10.1016/j.juro.2017.02.1779.
- Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Horie S, Byun S, Lee D, Dipaola R, Kim I. PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER. Journal Of Urology 2017, 197: e455-e456. DOI: 10.1016/j.juro.2017.02.1087.
- Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.
- Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.
- Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Kim I. Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate cancer. Journal Of Clinical Oncology 2017, 35: e578-e578. DOI: 10.1200/jco.2017.35.6_suppl.e578.
- Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.
- Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.
- Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.
- Byun J, Goyal S, Kim I, Parikh R. Local Therapy Improves Overall Survival in Patients with Newly Diagnosed Metastatic Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s183-s184. DOI: 10.1016/j.ijrobp.2016.06.459.
- Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 74. PMID: 27583246, PMCID: PMC4999522, DOI: 10.3389/fcell.2016.00074.
- Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.
- Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes. Investigative And Clinical Urology 2016, 57: s36-s43. PMID: 27326405, PMCID: PMC4910765, DOI: 10.4111/icu.2016.57.s1.s36.
- Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.
- Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice. Clinical Genitourinary Cancer 2016, 14: e617-e622. PMID: 27188968, DOI: 10.1016/j.clgc.2016.04.010.
- Kwon Y, Farber N, Yu J, Han C, Lee P, Kim J, Kim W, Kim I. PD50-10 LONGITUDINAL RECOVERY PATTERNS OF PENILE LENGTH AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR USE AFTER RADICAL PROSTATECTOMY. Journal Of Urology 2016, 195: e1189. DOI: 10.1016/j.juro.2016.02.2800.
- Kwon Y, Kang S, Wang W, Farber N, Radadia K, Lee P, Kim J, Hong J, Kim I. MP37-08 MISATTRIBUTION ERRORS IN UROLOGIC PROCEDURES FROM THE PROPUBLICA SURGEON SCORECARD. Journal Of Urology 2016, 195: e499-e500. DOI: 10.1016/j.juro.2016.02.1685.
- Han C, Lee G, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Kim I. MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE RENAL CELL CARCINOMA: A XENOGRAFT STUDY. Journal Of Urology 2016, 195: e1166. DOI: 10.1016/j.juro.2016.02.2645.
- Modi P, Faiena I, Patel N, Shen S, Singer E, Moore D, DiPaola R, Lu-Yao G, Kim I, Jang T. MP09-13 OUTCOMES OF MEN WITH LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE MANAGEMENT (CM). Journal Of Urology 2016, 195: e98. DOI: 10.1016/j.juro.2016.02.2300.
- Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e59. DOI: 10.1016/j.juro.2016.02.2096.
- Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. DOI: 10.1200/jco.2016.34.2_suppl.252.
- Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. 2016, 481-489. DOI: 10.1016/b978-0-12-800077-9.00052-9.
- Modi P, Faiena I, Kim I. Chapter 3 Androgen Receptor. 2016, 21-28. DOI: 10.1016/b978-0-12-800077-9.00003-7.
- Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.
- Sabaawy H, Bartucci M, Stein M, Kim I, Bertino J, DiPaola R, Ferrari A. Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy. Molecular Cancer Therapeutics 2015, 14: c36-c36. DOI: 10.1158/1535-7163.targ-15-c36.
- Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.
- Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.
- Wang D, Foran D, Ren J, Zhong H, Kim I, Qi X. Exploring automatic prostate histopathology image gleason grading via local structure modeling. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2015, 2015: 2649-2652. PMID: 26736836, PMCID: PMC4920598, DOI: 10.1109/embc.2015.7318936.
- Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.
- Bartucci M, Patrizii M, Huselid E, Yussuf S, Bansal N, Flaherty K, Tolkunov D, Zhong H, Stein M, Bertino J, DiPaola R, Kim I, Sabaawy H. Abstract 223: Generation of single cell-derived normal, benign and cancer mini-prostates from primary patient-derived tissues. 2015, 223-223. DOI: 10.1158/1538-7445.am2015-223.
- Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients. Journal Of Endourology 2015, 29: 1148-1151. PMID: 25891967, DOI: 10.1089/end.2015.0094.
- Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.
- Faiena I, Dombrovskiy V, Modi P, Patel N, Patel R, Salmasi A, Parihar J, Singer E, Kim I. Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy. Clinical Genitourinary Cancer 2015, 13: 447-452. PMID: 26065923, PMCID: PMC5176017, DOI: 10.1016/j.clgc.2015.05.004.
- Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.
- Patel N, Salmasi A, Dinizo M, Faiena I, Goyal R, Lee G, Hannan J, Bivalacqua T, Kohn J, Kim I. PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2015, 193: e766-e767. DOI: 10.1016/j.juro.2015.02.2255.
- Dinizo M, Shih W, Salmasi A, Faiena I, Modi P, Han M, Partin A, Eun D, Reese A, Llukani E, Giosto L, Wessel S, Trabulsi E, Lallas C, Yuh B, Wilson T, Marchalik D, Hwang J, Kundu S, Catalona W, Flum D, Eggener S, Negron E, Kim I. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2015, 193: e636. DOI: 10.1016/j.juro.2015.02.1698.
- Patel R, Modi P, Kim I. PD18-12 USE OF HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER ON THE NEUROVASCULAR BUNDLE DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: LONG TERM OUTCOMES. Journal Of Urology 2015, 193: e390-e391. DOI: 10.1016/j.juro.2015.02.697.
- Modi P, Ha Y, Lee G, Ahn H, Kim W, Kim I. MP47-05 ANDROGEN RECEPTOR MRNA EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA. Journal Of Urology 2015, 193: e553-e554. DOI: 10.1016/j.juro.2015.02.1525.
- Weiss R, Stein M, Mayer T, Salmasi A, Kim I, DiPaola R, Lattime E. MP72-10 PHASE I STUDY OF INTRAVESICAL RECOMBINANT FOWLPOX-GM-CSF (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO UNDERGOING CYSTECTOMY. Journal Of Urology 2015, 193: e924. DOI: 10.1016/j.juro.2015.02.2644.
- Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses. European Journal Of Cancer Care 2015, 24: 827-839. PMID: 25807856, PMCID: PMC4733598, DOI: 10.1111/ecc.12316.
- Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.
- Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.
- Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study. The World Journal Of Men's Health 2014, 32: 159-166. PMID: 25606565, PMCID: PMC4298819, DOI: 10.5534/wjmh.2014.32.3.159.
- Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.
- FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.
- Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World Journal Of Surgical Oncology 2014, 12: 288. PMID: 25227434, PMCID: PMC4176564, DOI: 10.1186/1477-7819-12-288.
- Ha Y, Kim I. Reply. Urology 2014, 84: 372. PMID: 24925832, DOI: 10.1016/j.urology.2014.02.040.
- Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery. Expert Opinion On Drug Discovery 2014, 9: 837-845. PMID: 24820058, DOI: 10.1517/17460441.2014.918947.
- Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology 2014, 14: 30. PMID: 24708639, PMCID: PMC4005471, DOI: 10.1186/1471-2490-14-30.
- Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER. Journal Of Urology 2014, 191: e896-e897. DOI: 10.1016/j.juro.2014.02.2428.
- Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA. Journal Of Urology 2014, 191: e821. DOI: 10.1016/j.juro.2014.02.2235.
- Salmasi A, Patel N, Lee G, Kim I. MP47-03 OFF-TARGET EFFECT OF SILDENAFIL IS NEUROPROTECTIVE VIA PHOSPHODIESTERASE TYPE-4. Journal Of Urology 2014, 191: e519. DOI: 10.1016/j.juro.2014.02.1456.
- Patel N, Salmasi A, Dinizo M, Goyal R, Hannan J, Lee G, Kohn J, Bivalacqua T, Kim I. MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2014, 191: e481. DOI: 10.1016/j.juro.2014.02.1168.
- Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES. Journal Of Urology 2014, 191: e927. DOI: 10.1016/j.juro.2014.02.2500.
- Parihar J, Ha Y, Kim I. Bladder neck contracture-incidence and management following contemporary robot assisted radical prostatectomy technique. Prostate International 2014, 2: 12-18. PMID: 24693529, PMCID: PMC3970984, DOI: 10.12954/pi.13034.
- Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.
- Lee G, Ha Y, Jung Y, Moon S, Kang H, Lee O, Joung J, Choi Y, Yun S, Kim W, Kim I. DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells. Annals Of Surgical Oncology 2014, 21: 538-545. PMID: 24562935, DOI: 10.1245/s10434-014-3560-6.
- Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.
- Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. British Journal Of Cancer 2014, 110: 1634-1644. PMID: 24518599, PMCID: PMC3960605, DOI: 10.1038/bjc.2014.23.
- Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2014, 1-4. DOI: 10.1007/978-3-642-27841-9_5930-2.
- Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.
- Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. PMID: 24377625, DOI: 10.7314/apjcp.2013.14.11.6913.
- Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.
- Bansal N, Davis S, Tereshchenko I, Budak‐Alpdogan T, Zhong H, Stein M, Kim I, DiPaola R, Bertino J, Sabaawy H. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. The Prostate 2013, 74: 187-200. PMID: 24154958, PMCID: PMC3939797, DOI: 10.1002/pros.22740.
- Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2013, 28: 172-177. PMID: 23987521, DOI: 10.1089/end.2013.0304.
- Kwon S, Lee G, Lee J, Iwakura Y, Kim W, Kim I. Mechanism of pro‐tumorigenic effect of BMP‐6: Neovascularization involving tumor‐associated macrophages and IL‐1α. The Prostate 2013, 74: 121-133. PMID: 24185914, DOI: 10.1002/pros.22734.
- Kim I, Bertino J, Sabaawy H. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells. 2013 DOI: 10.21236/ada598365.
- Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Investigative And Clinical Urology 2013, 54: 631-637. PMID: 24044099, PMCID: PMC3773595, DOI: 10.4111/kju.2013.54.9.631.
- Joung J, Ha Y, Singer E, Ercolani M, Favaretto R, Lee D, Kim W, Lee K, Kim I. Use of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience. Journal Of Endourology 2013, 27: 1230-1235. PMID: 23879531, PMCID: PMC3787401, DOI: 10.1089/end.2013.0345.
- Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey. Prostate Cancer And Prostatic Diseases 2013, 16: 341-345. PMID: 23917307, PMCID: PMC5767467, DOI: 10.1038/pcan.2013.24.
- Kim I. Editorial Comment. Urology 2013, 82: 583. PMID: 23876585, DOI: 10.1016/j.urology.2013.03.082.
- Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Science 2013, 104: 1027-1032. PMID: 23710822, PMCID: PMC7657257, DOI: 10.1111/cas.12206.
- Lee J, Lee G, Woo S, Ha Y, Kwon S, Kim W, Kim I. BMP-6 in Renal Cell Carcinoma Promotes Tumor Proliferation through IL-10–Dependent M2 Polarization of Tumor-Associated Macrophages. Cancer Research 2013, 73: 3604-3614. PMID: 23633487, DOI: 10.1158/0008-5472.can-12-4563.
- Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology 2013, 65: 693-700. PMID: 23759328, PMCID: PMC3825778, DOI: 10.1016/j.eururo.2013.05.023.
- Jung S, Oh S, Lee G, Chung J, Min K, Yoon J, Kim W, Ryu D, Kim I, Kang D. Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer. The World Journal Of Men's Health 2013, 31: 36-46. PMID: 23658864, PMCID: PMC3640151, DOI: 10.5534/wjmh.2013.31.1.36.
- Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. 967 METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: A MULTI-INSTITUTION STUDY. Journal Of Urology 2013, 189: e396-e397. DOI: 10.1016/j.juro.2013.02.548.
- Kim W, Kang H, Kim W, Lee S, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I. 2102 NATURAL HISTORY OF ASYMPTOMATIC RENAL STONES AND PREDICTION OF STONE-RELATED EVENTS. Journal Of Urology 2013, 189: e862. DOI: 10.1016/j.juro.2013.02.2011.
- Ha Y, Salmasi A, Kim J, Joung J, Lee D, Kim W, Kim I. 226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE. Journal Of Urology 2013, 189: e93. DOI: 10.1016/j.juro.2013.02.1606.
- Kim W, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I, Lee S, Kim W. 1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY. Journal Of Urology 2013, 189: e764-e765. DOI: 10.1016/j.juro.2013.02.2284.
- Kim I. Reply. Urology 2013, 81: 835-836. DOI: 10.1016/j.urology.2012.12.048.
- Kim Y, Yoon H, Kim J, Kang H, Min B, Kim S, Ha Y, Kim I, Ryu K, Lee S, Kim W. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling. International Journal Of Cancer 2013, 133: 1135-1142. PMID: 23436614, DOI: 10.1002/ijc.28121.
- Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.
- Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.
- Kim J, Ha Y, Jeong S, Lee D, Kim W, Kim I. Impact of Robot-assisted Radical Prostatectomy on Lower Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Longitudinal Study. Urology 2013, 81: 787-793. PMID: 23434100, DOI: 10.1016/j.urology.2012.12.038.
- Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.
- Ha Y, Goodin S, DiPaola R, Kim I. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Of Today 2013, 49: 7-13. PMID: 23362491, DOI: 10.1358/dot.2013.49.1.1910724.
- Joung J, Ha Y, Kim I. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Of Today 2013, 49: 483-90. PMID: 23977665, DOI: 10.1358/dot.2013.49.8.1968670.
- Ha Y, Chihara Y, Yoon H, Kim Y, Kim T, Woo S, Yun S, Kim I, Hirao Y, Kim W. Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in Sporadic Renal Cell Cancer. Urologia Internationalis 2012, 90: 233-239. PMID: 23295344, DOI: 10.1159/000345608.
- YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.
- Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.
- Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression. European Journal Of Surgical Oncology 2012, 38: 1095-1100. PMID: 22884471, DOI: 10.1016/j.ejso.2012.07.116.
- Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein. Molecular And Cellular Biochemistry 2012, 368: 147-153. PMID: 22707059, DOI: 10.1007/s11010-012-1353-4.
- Salmasi A, Han M, Kim I. Risk of more advanced cancer at surgery in African American men eligible for active surveillance. Journal Of Clinical Oncology 2012, 30: e15214-e15214. DOI: 10.1200/jco.2012.30.15_suppl.e15214.
- Kang D, Woo S, Lee D, Kim I. Incidence of Port-Site Hernias After Robot-Assisted Radical Prostatectomy with the Fascial Closure of Only the Midline 12-mm Port Site. Journal Of Endourology 2012, 26: 848-851. PMID: 22283233, DOI: 10.1089/end.2011.0630.
- Kim J, Kim W, Ha Y, Kim Y, Kim I, Lee S, Jang H, Kim W, Kim T, Yun S. 559 THE PROGNOSTIC SIGNIFICANCE OF RUNX3 METHYLATION IN NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS UNDERWENT TRANSURETHRAL RESECTION. Journal Of Urology 2012, 187: e229. DOI: 10.1016/j.juro.2012.02.634.
- HA Y, KIM Y, KIM J, Lee S, KIM I, Kim W, Seo J, Kim W, Chae Y, Yun S. 396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE (WHO G1 AND G2) BLADDER CANCER. Journal Of Urology 2012, 187: e162. DOI: 10.1016/j.juro.2012.02.460.
- Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S, Kim G, Choi Y, Moon S, Kim W. Tumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer. Urology 2012, 79: 1411.e1-1411.e6. PMID: 22446336, DOI: 10.1016/j.urology.2012.01.042.
- Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.
- Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. International Journal Of Cancer 2011, 131: e501-e507. PMID: 22025348, DOI: 10.1002/ijc.27319.
- Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.
- Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Of Andrology 2011, 13: 838-41. PMID: 21785442, PMCID: PMC3739560, DOI: 10.1038/aja.2011.54.
- Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research 2011, 17: 4523-4530. PMID: 21571867, DOI: 10.1158/1078-0432.ccr-10-2817.
- Woo S, Kim I. Editorial Comment for Rebuck et al. Journal Of Endourology 2011, 25: 960-961. PMID: 21574865, DOI: 10.1089/end.2011.0075.
- Lee G, Jung Y, Lee J, Kim W, Kim I. Bone morphogenetic protein 6-induced interleukin-1β expression in macrophages requires PU.1/Smad1 interaction. Molecular Immunology 2011, 48: 1540-1547. PMID: 21571370, DOI: 10.1016/j.molimm.2011.04.019.
- Jeong P, Ha Y, Cho I, Yun S, Yoo E, Kim I, Choi Y, Moon S, Kim W. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. Oncology Letters 2011, 2: 679-684. PMID: 22848249, PMCID: PMC3406413, DOI: 10.3892/ol.2011.309.
- Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Annals Of Oncology 2011, 23: 401-405. PMID: 21515665, DOI: 10.1093/annonc/mdr115.
- Ercolani M, Johnson K, Su D, Kim I. 1305 USE OF A HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE. Journal Of Urology 2011, 185: e522. DOI: 10.1016/j.juro.2011.02.1005.
- Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad. Urologic Oncology Seminars And Original Investigations 2011, 31: 63-67. PMID: 21396837, DOI: 10.1016/j.urolonc.2010.09.003.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop. The Prostate 2011, 71: 1525-1537. PMID: 21374653, DOI: 10.1002/pros.21369.
- Choi E, Jeong J, Kang D, Johnson K, Ercolani M, Jang T, Lee D, Kim W, Kim I. Impact of robot‐assisted radical prostatectomy on health‐related quality of life in patients with lower urinary tract symptoms. International Journal Of Urology 2011, 18: 297-303. PMID: 21342297, DOI: 10.1111/j.1442-2042.2011.02730.x.
- Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I, Moon S, Um H, Choi Y. A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine 2011, 17: 478-485. PMID: 21308147, PMCID: PMC3105150, DOI: 10.2119/molmed.2010.00274.
- Ha Y, Yan C, Jeong P, Kim W, Yun S, Kim I, Moon S, Kim W. GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal Of Korean Medical Science 2011, 26: 231-236. PMID: 21286014, PMCID: PMC3031007, DOI: 10.3346/jkms.2011.26.2.231.
- Jeong J, Choi E, Kang D, Lee D, Kim I. Impact of Partin nomogram on presurgical planning: intrafascial versus interfascial nerve sparing during robot-assisted radical prostatectomy. Journal Of Robotic Surgery 2011, 5: 121-125. PMID: 27637538, DOI: 10.1007/s11701-011-0247-x.
- Hong J, Kim I, Kim S. Transitional Cell Carcinoma. 2011, 3767-3769. DOI: 10.1007/978-3-642-16483-5_5930.
- Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.
- Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal Of Urology 2010, 185: 701-705. PMID: 21168882, DOI: 10.1016/j.juro.2010.09.081.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Kim I. Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling Pathways*. Journal Of Biological Chemistry 2010, 285: 39401-39408. PMID: 20889504, PMCID: PMC2998138, DOI: 10.1074/jbc.m110.103705.
- Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.
- Jeong J, Choi E, Kim I. Clavien Classification of Complications After the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience. Journal Of Endourology 2010, 24: 1457-1461. PMID: 20673148, DOI: 10.1089/end.2010.0027.
- Choi E, Jeong J, Kang D, Johnson K, Jang T, Kim I. Early assessment of patient satisfaction and health-related quality of life following robot-assisted radical prostatectomy. Journal Of Robotic Surgery 2010, 4: 221-227. PMID: 27627949, DOI: 10.1007/s11701-010-0212-0.
- Jeong J, Kang D, Lee G, Kim I. Bone Morphogenetic Protein Signaling: Implications in Urology. Investigative And Clinical Urology 2010, 51: 511-517. PMID: 20733955, PMCID: PMC2924553, DOI: 10.4111/kju.2010.51.8.511.
- Koo H, Lee D, Kim I. Renal Hilar Control During Laparoscopic Partial Nephrectomy: To Clamp or Not to Clamp. Journal Of Endourology 2010, 24: 1283-1287. PMID: 20629571, DOI: 10.1089/end.2009.0123.
- Kim I, Hwang E, Mmeje C, Ercolani M, Lee D. Impact of Posterior Urethral Plate Repair on Continence Following Robot-Assisted Laparoscopic Radical Prostatectomy. Yonsei Medical Journal 2010, 51: 427-431. PMID: 20376897, PMCID: PMC2852800, DOI: 10.3349/ymj.2010.51.3.427.
- Jeong J, Lamba S, Choi E, Kang D, Kim I. 291 STAGING IMPLICATIONS OF ANTERIOR PROSTATIC FAT PAD EXCISION DURING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY. Journal Of Urology 2010, 183: e115. DOI: 10.1016/j.juro.2010.02.353.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Choi E, Kim I. 1441 MECHANISM OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER: TUMOR-MACROPHARGE INTERACTION VIA BONE MORPHOGENETIC PROTEIN6-INTERLEUKIN6 LOOP. Journal Of Urology 2010, 183: e555. DOI: 10.1016/j.juro.2010.02.1134.
- Kang D, Jeong J, Choi E, Johnson K, Kim I. 1869 ANALYSIS OF PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS. Journal Of Urology 2010, 183: e726. DOI: 10.1016/j.juro.2010.02.1809.
- Mueller T, DaJusta D, Cha D, Kim I, Ankem M. Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy—A Novel and Simple Modification of the Pluck Technique. Urology 2009, 75: 187-192. PMID: 19913884, DOI: 10.1016/j.urology.2009.06.101.
- Potdevin L, Ercolani M, Jeong J, Kim I. Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in Robot-Assisted Laparoscopic Radical Prostatectomies. Journal Of Endourology 2009, 23: 1479-1484. PMID: 19694530, DOI: 10.1089/end.2009.0369.
- Potdevin L, Ercolani M, Kim I. COMPARING APPROACHES TO NERVE-SPARING IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL. Journal Of Urology 2009, 181: 578-579. DOI: 10.1016/s0022-5347(09)61630-x.
- Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 2009, 128: e758-e765. PMID: 19740337, PMCID: PMC2753926, DOI: 10.1111/j.1365-2567.2009.03079.x.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2009, 3040-3043. DOI: 10.1007/978-3-540-47648-1_5930.
- Jeon S, Kim I. Rebuttal. Journal Of Endourology 2008, 22: 1943-1944. DOI: 10.1089/end.2008.9773a.
- Jeon S, Kim I. Laparoscopic Partial Nephrectomy without Hilar Control. Journal Of Endourology 2008, 22: 1937-1940. PMID: 18811497, DOI: 10.1089/end.2008.9773.
- Krebs A, Borin J, Kim I, Jackson D, McDougall E, Clayman R. Evaluation of Practice Efficiency with a Novel Sheathed Flexible Cystoscope: A Randomized Controlled Trial. Urology 2007, 70: 883-887. PMID: 17919698, DOI: 10.1016/j.urology.2007.06.1112.
- Kwak C, Park Y, Kim I, Moon K, Ku J. Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor-β Superfamily, in Renal Cell Carcinoma. Journal Of Urology 2007, 178: 1062-1067. PMID: 17644140, DOI: 10.1016/j.juro.2007.05.005.
- Kim I, Eichel L, Edwards R, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, Woo E, McDougall E, Clayman R. Effects of Commonly Used Hemostatic Agents on the Porcine Collecting System. Journal Of Endourology 2007, 21: 652-654. PMID: 17638564, DOI: 10.1089/end.2007.9960.
- Mueller T, DaJusta D, Kim I, Hong J, Hwang J. 1489: the Patterns of Urinary Continence Following Robotic Assisted Radical Prostatectomy at Minimum 12 Months Follow-Up. Journal Of Urology 2007, 177: 491. DOI: 10.1016/s0022-5347(18)31690-2.
- Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106: 2610-2616. PMID: 16700038, DOI: 10.1002/cncr.21945.
- Kim I, Kim S. Role of bone morphogenetic proteins in transitional cell carcinoma cells. Cancer Letters 2006, 241: 118-123. PMID: 16500023, DOI: 10.1016/j.canlet.2005.10.009.
- ABDELSHEHID C, AHLERING M, CHOU D, PARK H, BASILLOTE J, LEE D, KIM I, EICHEL L, PROTSENKO D, WONG B, McDOUGALL E, CLAYMAN R. COMPARISON OF FLEXIBLE URETEROSCOPES: DEFLECTION, IRRIGANT FLOW AND OPTICAL CHARACTERISTICS. Journal Of Urology 2005, 173: 2017-2021. PMID: 15879808, DOI: 10.1097/01.ju.0000158139.65771.0a.
- Kim I, Eichel L, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, McDougall E, Clayman R. 1088: Comparison of Tisseel, Floseal, Coseal, and Bioglue in the Pig Urinary Collecting System. Journal Of Urology 2005, 173: 295. DOI: 10.1016/s0022-5347(18)35244-3.
- Kim I, Eichel L, Chou D, Abdelshehid C, Ahlering M, McDougall E, Clayman R. 649: Comparison of Laparoscopic Microwave Thermotherapy, Cryotherapy, and Radiofrequency Ablation for Destruction of Experimental VX-2 Renal Tumors in Rabbits. Journal Of Urology 2005, 173: 177. DOI: 10.1016/s0022-5347(18)34889-4.
- Kim I, Kim M, Kim S. Transforming Growth Factor-β: Biology and Clinical Relevance. BMB Reports 2005, 38: 1-8. PMID: 15715939, DOI: 10.5483/bmbrep.2005.38.1.001.
- Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research 2004, 64: 7355-7360. PMID: 15492256, DOI: 10.1158/0008-5472.can-04-0154.
- Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.
- Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.
- Shen S, Yu J, Kim I, Jian W, Matsumoto K, Kim M, Sonpavde G, Smith C, Ayala G, Younes M, Lerner S. 735: Differential Expression of Estrogen Receptor α and β in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue. Journal Of Urology 2004, 171: 195. DOI: 10.1016/s0022-5347(18)37984-9.
- Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. PMID: 14676131.
- Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.
- Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S. The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor-β Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*. Journal Of Biological Chemistry 2002, 277: 38557-38564. PMID: 12145312, DOI: 10.1074/jbc.m206786200.
- Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.
- Kim H, Kim B, Kim I, Mamura M, Do Hwan Seong, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.
- Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.
- Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.
- Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.
- KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION. Journal Of Urology 2001, 165: 903-904. DOI: 10.1097/00005392-200103000-00046.
- KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION. Journal Of Urology 2001, 165: 903-904. PMID: 11176503, DOI: 10.1016/s0022-5347(05)66561-5.
- Kim I, Schulam P. Laparoscopic nephrectomy for renal cell carcinoma. Current Urology Reports 2001, 2: 40-45. PMID: 12084294, DOI: 10.1007/s11934-001-0024-x.
- Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor. The Prostate 2000, 43: 118-124. PMID: 10754527, DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v.
- KIM I, SMITH C, OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS. Journal Of Urology 2000, 163: 237. DOI: 10.1097/00005392-200001000-00060.
- KIM I, SMITH C, OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS. Journal Of Urology 2000, 163: 237. PMID: 10604359, DOI: 10.1016/s0022-5347(05)68017-2.
- KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888.. DOI: 10.1097/00005392-199811000-00077.
- KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888. PMID: 9783979, DOI: 10.1016/s0022-5347(01)62437-6.
- Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. The Prostate 1998, 37: 51-59. PMID: 9721069, DOI: 10.1002/(sici)1097-0045(19980915)37:1<51::aid-pros8>3.0.co;2-b.
- Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. PMID: 9676836.
- Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.
- Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. PMID: 9533519.
- Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1. The Prostate 1997, 33: 64-71. PMID: 9294629, DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j.
- Yang S, Lee D, Hong S, Chung B, Kim I. Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonsei Medical Journal 1997, 38: 155-159. PMID: 9259615, DOI: 10.3349/ymj.1997.38.3.155.
- Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.
- Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.
- Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.
- Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Endocrinology 1996, 10: 107-15. PMID: 8838150, DOI: 10.1210/mend.10.1.8838150.
- Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.
- Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. PMID: 7530653, DOI: 10.1210/endo.136.2.7530653.
- Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. DOI: 10.1210/en.136.2.796.
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
- Yale UrologyOrchard Medical Center at St. Raphael’s Campus330 Orchard Street, Ste Suite 164New Haven, CT 06511
- Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830
Biography
Isaac Yi Kim, MD, PhD, MBA, chair of the Department of Urology at Yale School of Medicine, specializes in the treatment and management of prostate cancer with the goal of helping patients navigate and better understand their disease. Although he cares for all men with localized disease, his clinical and research focus is in men with high-risk disease, recurrence after radiation, and metastatic prostate cancer to lymph nodes, bones, lungs, and abdominal organs.
Dr. Kim is an expert in minimally invasive robotic surgery and has performed more than 2,100 robot-assisted radical prostatectomies, which are surgeries to remove the entire prostate gland. In addition, he has established a same-day radical prostatectomy program by using the latest-generation da Vinci robot to remove a diseased prostate through a single, one-inch incision in the abdomen. This results in less pain—and pain medication—for the patient, who usually goes home the same day of the surgery.
He was inspired to become a prostate surgeon during his medical training, when he decided he wanted to help men he saw struggling with complications such as impotence and incontinence, which often develop after prostate cancer surgery. Those post-surgery problems are less common with expert robotic surgeons, he says. “I see what an impact and a difference the surgical robot has made in helping our patients and allaying their fears.”
As a professor at Yale School of Medicine, Dr. Kim is also a surgeon-scientist who is studying the mechanism of prostate cancer treatment resistance. He is the principal investigator in clinical trials focused on advanced and metastatic prostate cancer, providing surgery in men with Stage IV prostate cancer. He says the traditional paradigm shows that when cancer cells have escaped the organ of origin, it’s too late to help. But his early data is showing that removing the prostate may enhance the effectiveness of chemotherapy and hormonal therapies for men with late-stage disease.
Dr. Kim says working at Yale Medicine is rewarding because of the rich history and tradition that values innovation and creativity, and he is focused on providing the latest treatments for men who have any stage of prostate cancer. “Yale Urology is one of the larger departments in the nation and we attract patients from regions far beyond New Haven. We’re really dedicated to delivering the most innovative care in the most compassionate manner,” he says. “When a patient and concerned family members come in with a prostate cancer diagnosis, and I’m able to take care of it and see how he recovers, it is truly a privilege and a blessing.”
Titles
- Professor of Urology
- Chair, Urology
- Chief, Urology
- Co-Leader, Cancer Signaling Networks, Yale Cancer Center
Education & Training
- MBAUniversity of Pennsylvania Wharton Business School, Finance (2017)
- Research FellowshipNational Institutes of Health (2005)
- Clinical FellowshipUniversity of California, Irvine (2005)
- ResidentBaylor College of Medicine (2003)
- MDNorthwestern University, Feinberg School of Medicine (1997)
- PhDNorthwestern University Graduate School, Tumor Cell Biology (1996)
Additional Information
- AB of Urology, Urology (2007)
- Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K, Tuiche M, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott J, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir S, Mitrofanova A. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications 2024, 15: 352. PMID: 38191557, PMCID: PMC10774320, DOI: 10.1038/s41467-024-44686-5.
- Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.
- Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries. Frontiers In Urology 2023, 2: 1069265. DOI: 10.3389/fruro.2022.1069265.
- Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.
- Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.
- Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.
- Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome. Analyst 2022, 147: 3043-3054. PMID: 35642979, DOI: 10.1039/d2an00676f.
- Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.
- Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.
- Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Patel H, Sterling J, Srivastava A, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC). Journal Of The American College Of Surgeons 2021, 233: e230-e231. DOI: 10.1016/j.jamcollsurg.2021.08.623.
- Chua K, Mikail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of The American College Of Surgeons 2021, 233: s310-s311. DOI: 10.1016/j.jamcollsurg.2021.07.643.
- Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.
- Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.
- Chua K, Mikhail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of Urology 2021, 207: 684-691. PMID: 34694164, DOI: 10.1097/ju.0000000000002258.
- Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.
- Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 146-146. DOI: 10.1200/jco.2020.39.28_suppl.146.
- Sterling J, Kim I. EDITORIAL COMMENT. Urology 2021, 155: 151. PMID: 34488998, DOI: 10.1016/j.urology.2021.01.065.
- Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.
- Piao X, Hwang B, Jeong P, Byun Y, Kang H, Seo S, Kim W, Lee J, Ha Y, Lee Y, Kim I, Choi Y, Cha E, Moon S, Yun S, Kim W. Collagen type VI-α1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal Of Oncology 2021, 59: 37. PMID: 33982770, DOI: 10.3892/ijo.2021.5217.
- Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.
- Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.
- Mikhail M, Chua K, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. Journal Of Clinical Oncology 2021, 39: 357-357. DOI: 10.1200/jco.2021.39.6_suppl.357.
- Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.
- Srivastava A, Patel H, Kim S, Shinder B, Sterling J, Tabakin A, Polotti C, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Patel H, Jang T, Singer E. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Journal Of Clinical Oncology 2021, 39: 283-283. DOI: 10.1200/jco.2021.39.6_suppl.283.
- Manne S, Kashy D, Myers‐Virtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer. European Journal Of Cancer Care 2021, 30: e13401. PMID: 33586282, PMCID: PMC9165020, DOI: 10.1111/ecc.13401.
- Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.
- Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.
- Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.
- Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.
- Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.
- Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis. Journal Of Biophotonics 2020, 14: e202000275. PMID: 32909380, DOI: 10.1002/jbio.202000275.
- Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.
- Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.
- Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.
- Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.
- Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.
- Sterling J, Jang T, Kim I. EDITORIAL COMMENT. Urology 2020, 135: 122. PMID: 31895674, DOI: 10.1016/j.urology.2019.07.052.
- Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.
- Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.
- Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.
- Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.
- Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.
- Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.
- Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. PMID: 31139700, PMCID: PMC6526358.
- Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.
- Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556802.43534.0b.
- Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555316.15591.47.
- Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.
- Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial. British Journal Of Health Psychology 2019, 24: 396-418. PMID: 30852854, PMCID: PMC8279429, DOI: 10.1111/bjhp.12359.
- Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. DOI: 10.1200/jco.2019.37.7_suppl.672.
- Sterling J, Rivera-Nunez Z, Farber N, Modi P, Radadia K, Kim S, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses. Journal Of Clinical Oncology 2019, 37: 648-648. DOI: 10.1200/jco.2019.37.7_suppl.648.
- Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.
- Faiena I, Kim I, Jang T. Multimodal treatments for advanced prostate cancer. Oncotarget 2019, 10: 255-256. PMID: 30719221, PMCID: PMC6349456, DOI: 10.18632/oncotarget.26525.
- Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.
- Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.
- Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.
- Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.
- Manne S, Kashy D, Zaider T, Lee D, Kim I, Heckman C, Penedo F, Kissane D, Virtue S. Interpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners. Journal Of Family Psychology 2018, 32: 664-675. PMID: 29771551, PMCID: PMC6072581, DOI: 10.1037/fam0000404.
- Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 PMID: 30714046, PMCID: PMC6358174.
- Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget 2018, 9: 21359-21365. PMID: 29765545, PMCID: PMC5940363, DOI: 10.18632/oncotarget.25103.
- Ahlering T, Huynh L, Kamaljot K, Williams S, Osann K, Joseph J, Lee D, Lee D, Davis J, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. MP82-08 UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING. Journal Of Urology 2018, 199: e1108-e1109. DOI: 10.1016/j.juro.2018.02.2736.
- Diefenbach M, Hudson S, Marziliano A, Fleszar S, Tagai E, Bator A, Chen D, Cox B, Hall S, Kim I, Kim S, Kutikov A, Miyamoto C, Potters L, Reese A, Vira M, Torre G, DeCoster C, Bhat R, Hui S, Miller S. PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS. Journal Of Urology 2018, 199: e570. DOI: 10.1016/j.juro.2018.02.1382.
- Farber N, Rivera-Nunez Z, Kim S, Radadia K, Modi P, Goyal S, Parikh R, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: A PROPENSITY SCORE-WEIGHTED ANALYSIS. Journal Of Urology 2018, 199: e456. DOI: 10.1016/j.juro.2018.02.1135.
- Tabakin A, Kim S, Polotti C, Rivera-Núñez Z, Sterling J, Modi P, Farber N, Radadia K, Parikh R, Goyal S, Weiss R, Kim I, Elsamra S, Singer E, Jang T. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014. Journal Of Urology 2018, 199: e1129. DOI: 10.1016/j.juro.2018.02.2780.
- Ahlering T, Huynh L, Kaler K, Williams S, Osann K, Joseph J, Lee D, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. 269 Unintended consequences of decreased PSA-based prostate cancer screening. European Urology Open Science 2018, 17: e376-e377. DOI: 10.1016/s1569-9056(18)31114-x.
- Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.
- Kim W, Kim Y, Jeong P, Seo S, Kang H, Kim Y, Yun S, Lee S, Moon S, Choi Y, Lee G, Kim I, Kim W. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget 2018, 9: 14354-14365. PMID: 29581849, PMCID: PMC5865675, DOI: 10.18632/oncotarget.24436.
- Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M. The American Journal Of Chinese Medicine 2018, 46: 689-705. PMID: 29595070, DOI: 10.1142/s0192415x18500362.
- Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 2017, 5: 109783-109790. PMID: 29312648, PMCID: PMC5752561, DOI: 10.18632/oncotarget.21297.
- Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer. International Journal Of Surgery Oncology 2017, 2: e13. PMID: 29177226, PMCID: PMC5673152, DOI: 10.1097/ij9.0000000000000013.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2017, 4637-4640. DOI: 10.1007/978-3-662-46875-3_5930.
- Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis. International Journal Of Oncology 2017, 51: 204-212. PMID: 28498422, DOI: 10.3892/ijo.2017.3993.
- Parikh R, Kim I. Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Journal Of Clinical Oncology 2017, 35: jco.2017.72.484. PMID: 28471706, DOI: 10.1200/jco.2017.72.4849.
- Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Ahn H, Kim W, Singer E, Kim I. MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS IN RENAL CELL CARCINOMA. Journal Of Urology 2017, 197: e792-e793. DOI: 10.1016/j.juro.2017.02.1845.
- Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal Of Urology 2017, 197: e765. DOI: 10.1016/j.juro.2017.02.1779.
- Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Horie S, Byun S, Lee D, Dipaola R, Kim I. PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER. Journal Of Urology 2017, 197: e455-e456. DOI: 10.1016/j.juro.2017.02.1087.
- Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.
- Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.
- Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Kim I. Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate cancer. Journal Of Clinical Oncology 2017, 35: e578-e578. DOI: 10.1200/jco.2017.35.6_suppl.e578.
- Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.
- Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.
- Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.
- Byun J, Goyal S, Kim I, Parikh R. Local Therapy Improves Overall Survival in Patients with Newly Diagnosed Metastatic Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s183-s184. DOI: 10.1016/j.ijrobp.2016.06.459.
- Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 74. PMID: 27583246, PMCID: PMC4999522, DOI: 10.3389/fcell.2016.00074.
- Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.
- Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes. Investigative And Clinical Urology 2016, 57: s36-s43. PMID: 27326405, PMCID: PMC4910765, DOI: 10.4111/icu.2016.57.s1.s36.
- Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.
- Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice. Clinical Genitourinary Cancer 2016, 14: e617-e622. PMID: 27188968, DOI: 10.1016/j.clgc.2016.04.010.
- Kwon Y, Farber N, Yu J, Han C, Lee P, Kim J, Kim W, Kim I. PD50-10 LONGITUDINAL RECOVERY PATTERNS OF PENILE LENGTH AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR USE AFTER RADICAL PROSTATECTOMY. Journal Of Urology 2016, 195: e1189. DOI: 10.1016/j.juro.2016.02.2800.
- Kwon Y, Kang S, Wang W, Farber N, Radadia K, Lee P, Kim J, Hong J, Kim I. MP37-08 MISATTRIBUTION ERRORS IN UROLOGIC PROCEDURES FROM THE PROPUBLICA SURGEON SCORECARD. Journal Of Urology 2016, 195: e499-e500. DOI: 10.1016/j.juro.2016.02.1685.
- Han C, Lee G, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Kim I. MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE RENAL CELL CARCINOMA: A XENOGRAFT STUDY. Journal Of Urology 2016, 195: e1166. DOI: 10.1016/j.juro.2016.02.2645.
- Modi P, Faiena I, Patel N, Shen S, Singer E, Moore D, DiPaola R, Lu-Yao G, Kim I, Jang T. MP09-13 OUTCOMES OF MEN WITH LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE MANAGEMENT (CM). Journal Of Urology 2016, 195: e98. DOI: 10.1016/j.juro.2016.02.2300.
- Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e59. DOI: 10.1016/j.juro.2016.02.2096.
- Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. DOI: 10.1200/jco.2016.34.2_suppl.252.
- Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. 2016, 481-489. DOI: 10.1016/b978-0-12-800077-9.00052-9.
- Modi P, Faiena I, Kim I. Chapter 3 Androgen Receptor. 2016, 21-28. DOI: 10.1016/b978-0-12-800077-9.00003-7.
- Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.
- Sabaawy H, Bartucci M, Stein M, Kim I, Bertino J, DiPaola R, Ferrari A. Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy. Molecular Cancer Therapeutics 2015, 14: c36-c36. DOI: 10.1158/1535-7163.targ-15-c36.
- Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.
- Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.
- Wang D, Foran D, Ren J, Zhong H, Kim I, Qi X. Exploring automatic prostate histopathology image gleason grading via local structure modeling. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2015, 2015: 2649-2652. PMID: 26736836, PMCID: PMC4920598, DOI: 10.1109/embc.2015.7318936.
- Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.
- Bartucci M, Patrizii M, Huselid E, Yussuf S, Bansal N, Flaherty K, Tolkunov D, Zhong H, Stein M, Bertino J, DiPaola R, Kim I, Sabaawy H. Abstract 223: Generation of single cell-derived normal, benign and cancer mini-prostates from primary patient-derived tissues. 2015, 223-223. DOI: 10.1158/1538-7445.am2015-223.
- Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients. Journal Of Endourology 2015, 29: 1148-1151. PMID: 25891967, DOI: 10.1089/end.2015.0094.
- Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.
- Faiena I, Dombrovskiy V, Modi P, Patel N, Patel R, Salmasi A, Parihar J, Singer E, Kim I. Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy. Clinical Genitourinary Cancer 2015, 13: 447-452. PMID: 26065923, PMCID: PMC5176017, DOI: 10.1016/j.clgc.2015.05.004.
- Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.
- Patel N, Salmasi A, Dinizo M, Faiena I, Goyal R, Lee G, Hannan J, Bivalacqua T, Kohn J, Kim I. PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2015, 193: e766-e767. DOI: 10.1016/j.juro.2015.02.2255.
- Dinizo M, Shih W, Salmasi A, Faiena I, Modi P, Han M, Partin A, Eun D, Reese A, Llukani E, Giosto L, Wessel S, Trabulsi E, Lallas C, Yuh B, Wilson T, Marchalik D, Hwang J, Kundu S, Catalona W, Flum D, Eggener S, Negron E, Kim I. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2015, 193: e636. DOI: 10.1016/j.juro.2015.02.1698.
- Patel R, Modi P, Kim I. PD18-12 USE OF HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER ON THE NEUROVASCULAR BUNDLE DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: LONG TERM OUTCOMES. Journal Of Urology 2015, 193: e390-e391. DOI: 10.1016/j.juro.2015.02.697.
- Modi P, Ha Y, Lee G, Ahn H, Kim W, Kim I. MP47-05 ANDROGEN RECEPTOR MRNA EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA. Journal Of Urology 2015, 193: e553-e554. DOI: 10.1016/j.juro.2015.02.1525.
- Weiss R, Stein M, Mayer T, Salmasi A, Kim I, DiPaola R, Lattime E. MP72-10 PHASE I STUDY OF INTRAVESICAL RECOMBINANT FOWLPOX-GM-CSF (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO UNDERGOING CYSTECTOMY. Journal Of Urology 2015, 193: e924. DOI: 10.1016/j.juro.2015.02.2644.
- Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses. European Journal Of Cancer Care 2015, 24: 827-839. PMID: 25807856, PMCID: PMC4733598, DOI: 10.1111/ecc.12316.
- Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.
- Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.
- Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study. The World Journal Of Men's Health 2014, 32: 159-166. PMID: 25606565, PMCID: PMC4298819, DOI: 10.5534/wjmh.2014.32.3.159.
- Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.
- FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.
- Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World Journal Of Surgical Oncology 2014, 12: 288. PMID: 25227434, PMCID: PMC4176564, DOI: 10.1186/1477-7819-12-288.
- Ha Y, Kim I. Reply. Urology 2014, 84: 372. PMID: 24925832, DOI: 10.1016/j.urology.2014.02.040.
- Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery. Expert Opinion On Drug Discovery 2014, 9: 837-845. PMID: 24820058, DOI: 10.1517/17460441.2014.918947.
- Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology 2014, 14: 30. PMID: 24708639, PMCID: PMC4005471, DOI: 10.1186/1471-2490-14-30.
- Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER. Journal Of Urology 2014, 191: e896-e897. DOI: 10.1016/j.juro.2014.02.2428.
- Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA. Journal Of Urology 2014, 191: e821. DOI: 10.1016/j.juro.2014.02.2235.
- Salmasi A, Patel N, Lee G, Kim I. MP47-03 OFF-TARGET EFFECT OF SILDENAFIL IS NEUROPROTECTIVE VIA PHOSPHODIESTERASE TYPE-4. Journal Of Urology 2014, 191: e519. DOI: 10.1016/j.juro.2014.02.1456.
- Patel N, Salmasi A, Dinizo M, Goyal R, Hannan J, Lee G, Kohn J, Bivalacqua T, Kim I. MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2014, 191: e481. DOI: 10.1016/j.juro.2014.02.1168.
- Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES. Journal Of Urology 2014, 191: e927. DOI: 10.1016/j.juro.2014.02.2500.
- Parihar J, Ha Y, Kim I. Bladder neck contracture-incidence and management following contemporary robot assisted radical prostatectomy technique. Prostate International 2014, 2: 12-18. PMID: 24693529, PMCID: PMC3970984, DOI: 10.12954/pi.13034.
- Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.
- Lee G, Ha Y, Jung Y, Moon S, Kang H, Lee O, Joung J, Choi Y, Yun S, Kim W, Kim I. DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells. Annals Of Surgical Oncology 2014, 21: 538-545. PMID: 24562935, DOI: 10.1245/s10434-014-3560-6.
- Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.
- Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. British Journal Of Cancer 2014, 110: 1634-1644. PMID: 24518599, PMCID: PMC3960605, DOI: 10.1038/bjc.2014.23.
- Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2014, 1-4. DOI: 10.1007/978-3-642-27841-9_5930-2.
- Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.
- Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. PMID: 24377625, DOI: 10.7314/apjcp.2013.14.11.6913.
- Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.
- Bansal N, Davis S, Tereshchenko I, Budak‐Alpdogan T, Zhong H, Stein M, Kim I, DiPaola R, Bertino J, Sabaawy H. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. The Prostate 2013, 74: 187-200. PMID: 24154958, PMCID: PMC3939797, DOI: 10.1002/pros.22740.
- Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2013, 28: 172-177. PMID: 23987521, DOI: 10.1089/end.2013.0304.
- Kwon S, Lee G, Lee J, Iwakura Y, Kim W, Kim I. Mechanism of pro‐tumorigenic effect of BMP‐6: Neovascularization involving tumor‐associated macrophages and IL‐1α. The Prostate 2013, 74: 121-133. PMID: 24185914, DOI: 10.1002/pros.22734.
- Kim I, Bertino J, Sabaawy H. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells. 2013 DOI: 10.21236/ada598365.
- Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Investigative And Clinical Urology 2013, 54: 631-637. PMID: 24044099, PMCID: PMC3773595, DOI: 10.4111/kju.2013.54.9.631.
- Joung J, Ha Y, Singer E, Ercolani M, Favaretto R, Lee D, Kim W, Lee K, Kim I. Use of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience. Journal Of Endourology 2013, 27: 1230-1235. PMID: 23879531, PMCID: PMC3787401, DOI: 10.1089/end.2013.0345.
- Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey. Prostate Cancer And Prostatic Diseases 2013, 16: 341-345. PMID: 23917307, PMCID: PMC5767467, DOI: 10.1038/pcan.2013.24.
- Kim I. Editorial Comment. Urology 2013, 82: 583. PMID: 23876585, DOI: 10.1016/j.urology.2013.03.082.
- Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Science 2013, 104: 1027-1032. PMID: 23710822, PMCID: PMC7657257, DOI: 10.1111/cas.12206.
- Lee J, Lee G, Woo S, Ha Y, Kwon S, Kim W, Kim I. BMP-6 in Renal Cell Carcinoma Promotes Tumor Proliferation through IL-10–Dependent M2 Polarization of Tumor-Associated Macrophages. Cancer Research 2013, 73: 3604-3614. PMID: 23633487, DOI: 10.1158/0008-5472.can-12-4563.
- Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology 2013, 65: 693-700. PMID: 23759328, PMCID: PMC3825778, DOI: 10.1016/j.eururo.2013.05.023.
- Jung S, Oh S, Lee G, Chung J, Min K, Yoon J, Kim W, Ryu D, Kim I, Kang D. Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer. The World Journal Of Men's Health 2013, 31: 36-46. PMID: 23658864, PMCID: PMC3640151, DOI: 10.5534/wjmh.2013.31.1.36.
- Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. 967 METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: A MULTI-INSTITUTION STUDY. Journal Of Urology 2013, 189: e396-e397. DOI: 10.1016/j.juro.2013.02.548.
- Kim W, Kang H, Kim W, Lee S, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I. 2102 NATURAL HISTORY OF ASYMPTOMATIC RENAL STONES AND PREDICTION OF STONE-RELATED EVENTS. Journal Of Urology 2013, 189: e862. DOI: 10.1016/j.juro.2013.02.2011.
- Ha Y, Salmasi A, Kim J, Joung J, Lee D, Kim W, Kim I. 226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE. Journal Of Urology 2013, 189: e93. DOI: 10.1016/j.juro.2013.02.1606.
- Kim W, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I, Lee S, Kim W. 1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY. Journal Of Urology 2013, 189: e764-e765. DOI: 10.1016/j.juro.2013.02.2284.
- Kim I. Reply. Urology 2013, 81: 835-836. DOI: 10.1016/j.urology.2012.12.048.
- Kim Y, Yoon H, Kim J, Kang H, Min B, Kim S, Ha Y, Kim I, Ryu K, Lee S, Kim W. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling. International Journal Of Cancer 2013, 133: 1135-1142. PMID: 23436614, DOI: 10.1002/ijc.28121.
- Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.
- Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.
- Kim J, Ha Y, Jeong S, Lee D, Kim W, Kim I. Impact of Robot-assisted Radical Prostatectomy on Lower Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Longitudinal Study. Urology 2013, 81: 787-793. PMID: 23434100, DOI: 10.1016/j.urology.2012.12.038.
- Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.
- Ha Y, Goodin S, DiPaola R, Kim I. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Of Today 2013, 49: 7-13. PMID: 23362491, DOI: 10.1358/dot.2013.49.1.1910724.
- Joung J, Ha Y, Kim I. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Of Today 2013, 49: 483-90. PMID: 23977665, DOI: 10.1358/dot.2013.49.8.1968670.
- Ha Y, Chihara Y, Yoon H, Kim Y, Kim T, Woo S, Yun S, Kim I, Hirao Y, Kim W. Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in Sporadic Renal Cell Cancer. Urologia Internationalis 2012, 90: 233-239. PMID: 23295344, DOI: 10.1159/000345608.
- YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.
- Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.
- Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression. European Journal Of Surgical Oncology 2012, 38: 1095-1100. PMID: 22884471, DOI: 10.1016/j.ejso.2012.07.116.
- Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein. Molecular And Cellular Biochemistry 2012, 368: 147-153. PMID: 22707059, DOI: 10.1007/s11010-012-1353-4.
- Salmasi A, Han M, Kim I. Risk of more advanced cancer at surgery in African American men eligible for active surveillance. Journal Of Clinical Oncology 2012, 30: e15214-e15214. DOI: 10.1200/jco.2012.30.15_suppl.e15214.
- Kang D, Woo S, Lee D, Kim I. Incidence of Port-Site Hernias After Robot-Assisted Radical Prostatectomy with the Fascial Closure of Only the Midline 12-mm Port Site. Journal Of Endourology 2012, 26: 848-851. PMID: 22283233, DOI: 10.1089/end.2011.0630.
- Kim J, Kim W, Ha Y, Kim Y, Kim I, Lee S, Jang H, Kim W, Kim T, Yun S. 559 THE PROGNOSTIC SIGNIFICANCE OF RUNX3 METHYLATION IN NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS UNDERWENT TRANSURETHRAL RESECTION. Journal Of Urology 2012, 187: e229. DOI: 10.1016/j.juro.2012.02.634.
- HA Y, KIM Y, KIM J, Lee S, KIM I, Kim W, Seo J, Kim W, Chae Y, Yun S. 396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE (WHO G1 AND G2) BLADDER CANCER. Journal Of Urology 2012, 187: e162. DOI: 10.1016/j.juro.2012.02.460.
- Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S, Kim G, Choi Y, Moon S, Kim W. Tumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer. Urology 2012, 79: 1411.e1-1411.e6. PMID: 22446336, DOI: 10.1016/j.urology.2012.01.042.
- Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.
- Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. International Journal Of Cancer 2011, 131: e501-e507. PMID: 22025348, DOI: 10.1002/ijc.27319.
- Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.
- Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Of Andrology 2011, 13: 838-41. PMID: 21785442, PMCID: PMC3739560, DOI: 10.1038/aja.2011.54.
- Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research 2011, 17: 4523-4530. PMID: 21571867, DOI: 10.1158/1078-0432.ccr-10-2817.
- Woo S, Kim I. Editorial Comment for Rebuck et al. Journal Of Endourology 2011, 25: 960-961. PMID: 21574865, DOI: 10.1089/end.2011.0075.
- Lee G, Jung Y, Lee J, Kim W, Kim I. Bone morphogenetic protein 6-induced interleukin-1β expression in macrophages requires PU.1/Smad1 interaction. Molecular Immunology 2011, 48: 1540-1547. PMID: 21571370, DOI: 10.1016/j.molimm.2011.04.019.
- Jeong P, Ha Y, Cho I, Yun S, Yoo E, Kim I, Choi Y, Moon S, Kim W. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. Oncology Letters 2011, 2: 679-684. PMID: 22848249, PMCID: PMC3406413, DOI: 10.3892/ol.2011.309.
- Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Annals Of Oncology 2011, 23: 401-405. PMID: 21515665, DOI: 10.1093/annonc/mdr115.
- Ercolani M, Johnson K, Su D, Kim I. 1305 USE OF A HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE. Journal Of Urology 2011, 185: e522. DOI: 10.1016/j.juro.2011.02.1005.
- Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad. Urologic Oncology Seminars And Original Investigations 2011, 31: 63-67. PMID: 21396837, DOI: 10.1016/j.urolonc.2010.09.003.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop. The Prostate 2011, 71: 1525-1537. PMID: 21374653, DOI: 10.1002/pros.21369.
- Choi E, Jeong J, Kang D, Johnson K, Ercolani M, Jang T, Lee D, Kim W, Kim I. Impact of robot‐assisted radical prostatectomy on health‐related quality of life in patients with lower urinary tract symptoms. International Journal Of Urology 2011, 18: 297-303. PMID: 21342297, DOI: 10.1111/j.1442-2042.2011.02730.x.
- Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I, Moon S, Um H, Choi Y. A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine 2011, 17: 478-485. PMID: 21308147, PMCID: PMC3105150, DOI: 10.2119/molmed.2010.00274.
- Ha Y, Yan C, Jeong P, Kim W, Yun S, Kim I, Moon S, Kim W. GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal Of Korean Medical Science 2011, 26: 231-236. PMID: 21286014, PMCID: PMC3031007, DOI: 10.3346/jkms.2011.26.2.231.
- Jeong J, Choi E, Kang D, Lee D, Kim I. Impact of Partin nomogram on presurgical planning: intrafascial versus interfascial nerve sparing during robot-assisted radical prostatectomy. Journal Of Robotic Surgery 2011, 5: 121-125. PMID: 27637538, DOI: 10.1007/s11701-011-0247-x.
- Hong J, Kim I, Kim S. Transitional Cell Carcinoma. 2011, 3767-3769. DOI: 10.1007/978-3-642-16483-5_5930.
- Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.
- Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal Of Urology 2010, 185: 701-705. PMID: 21168882, DOI: 10.1016/j.juro.2010.09.081.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Kim I. Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling Pathways*. Journal Of Biological Chemistry 2010, 285: 39401-39408. PMID: 20889504, PMCID: PMC2998138, DOI: 10.1074/jbc.m110.103705.
- Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.
- Jeong J, Choi E, Kim I. Clavien Classification of Complications After the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience. Journal Of Endourology 2010, 24: 1457-1461. PMID: 20673148, DOI: 10.1089/end.2010.0027.
- Choi E, Jeong J, Kang D, Johnson K, Jang T, Kim I. Early assessment of patient satisfaction and health-related quality of life following robot-assisted radical prostatectomy. Journal Of Robotic Surgery 2010, 4: 221-227. PMID: 27627949, DOI: 10.1007/s11701-010-0212-0.
- Jeong J, Kang D, Lee G, Kim I. Bone Morphogenetic Protein Signaling: Implications in Urology. Investigative And Clinical Urology 2010, 51: 511-517. PMID: 20733955, PMCID: PMC2924553, DOI: 10.4111/kju.2010.51.8.511.
- Koo H, Lee D, Kim I. Renal Hilar Control During Laparoscopic Partial Nephrectomy: To Clamp or Not to Clamp. Journal Of Endourology 2010, 24: 1283-1287. PMID: 20629571, DOI: 10.1089/end.2009.0123.
- Kim I, Hwang E, Mmeje C, Ercolani M, Lee D. Impact of Posterior Urethral Plate Repair on Continence Following Robot-Assisted Laparoscopic Radical Prostatectomy. Yonsei Medical Journal 2010, 51: 427-431. PMID: 20376897, PMCID: PMC2852800, DOI: 10.3349/ymj.2010.51.3.427.
- Jeong J, Lamba S, Choi E, Kang D, Kim I. 291 STAGING IMPLICATIONS OF ANTERIOR PROSTATIC FAT PAD EXCISION DURING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY. Journal Of Urology 2010, 183: e115. DOI: 10.1016/j.juro.2010.02.353.
- Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Choi E, Kim I. 1441 MECHANISM OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER: TUMOR-MACROPHARGE INTERACTION VIA BONE MORPHOGENETIC PROTEIN6-INTERLEUKIN6 LOOP. Journal Of Urology 2010, 183: e555. DOI: 10.1016/j.juro.2010.02.1134.
- Kang D, Jeong J, Choi E, Johnson K, Kim I. 1869 ANALYSIS OF PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS. Journal Of Urology 2010, 183: e726. DOI: 10.1016/j.juro.2010.02.1809.
- Mueller T, DaJusta D, Cha D, Kim I, Ankem M. Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy—A Novel and Simple Modification of the Pluck Technique. Urology 2009, 75: 187-192. PMID: 19913884, DOI: 10.1016/j.urology.2009.06.101.
- Potdevin L, Ercolani M, Jeong J, Kim I. Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in Robot-Assisted Laparoscopic Radical Prostatectomies. Journal Of Endourology 2009, 23: 1479-1484. PMID: 19694530, DOI: 10.1089/end.2009.0369.
- Potdevin L, Ercolani M, Kim I. COMPARING APPROACHES TO NERVE-SPARING IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL. Journal Of Urology 2009, 181: 578-579. DOI: 10.1016/s0022-5347(09)61630-x.
- Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 2009, 128: e758-e765. PMID: 19740337, PMCID: PMC2753926, DOI: 10.1111/j.1365-2567.2009.03079.x.
- Hong J, Kim S, Kim I. Transitional Cell Carcinoma. 2009, 3040-3043. DOI: 10.1007/978-3-540-47648-1_5930.
- Jeon S, Kim I. Rebuttal. Journal Of Endourology 2008, 22: 1943-1944. DOI: 10.1089/end.2008.9773a.
- Jeon S, Kim I. Laparoscopic Partial Nephrectomy without Hilar Control. Journal Of Endourology 2008, 22: 1937-1940. PMID: 18811497, DOI: 10.1089/end.2008.9773.
- Krebs A, Borin J, Kim I, Jackson D, McDougall E, Clayman R. Evaluation of Practice Efficiency with a Novel Sheathed Flexible Cystoscope: A Randomized Controlled Trial. Urology 2007, 70: 883-887. PMID: 17919698, DOI: 10.1016/j.urology.2007.06.1112.
- Kwak C, Park Y, Kim I, Moon K, Ku J. Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor-β Superfamily, in Renal Cell Carcinoma. Journal Of Urology 2007, 178: 1062-1067. PMID: 17644140, DOI: 10.1016/j.juro.2007.05.005.
- Kim I, Eichel L, Edwards R, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, Woo E, McDougall E, Clayman R. Effects of Commonly Used Hemostatic Agents on the Porcine Collecting System. Journal Of Endourology 2007, 21: 652-654. PMID: 17638564, DOI: 10.1089/end.2007.9960.
- Mueller T, DaJusta D, Kim I, Hong J, Hwang J. 1489: the Patterns of Urinary Continence Following Robotic Assisted Radical Prostatectomy at Minimum 12 Months Follow-Up. Journal Of Urology 2007, 177: 491. DOI: 10.1016/s0022-5347(18)31690-2.
- Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106: 2610-2616. PMID: 16700038, DOI: 10.1002/cncr.21945.
- Kim I, Kim S. Role of bone morphogenetic proteins in transitional cell carcinoma cells. Cancer Letters 2006, 241: 118-123. PMID: 16500023, DOI: 10.1016/j.canlet.2005.10.009.
- ABDELSHEHID C, AHLERING M, CHOU D, PARK H, BASILLOTE J, LEE D, KIM I, EICHEL L, PROTSENKO D, WONG B, McDOUGALL E, CLAYMAN R. COMPARISON OF FLEXIBLE URETEROSCOPES: DEFLECTION, IRRIGANT FLOW AND OPTICAL CHARACTERISTICS. Journal Of Urology 2005, 173: 2017-2021. PMID: 15879808, DOI: 10.1097/01.ju.0000158139.65771.0a.
- Kim I, Eichel L, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, McDougall E, Clayman R. 1088: Comparison of Tisseel, Floseal, Coseal, and Bioglue in the Pig Urinary Collecting System. Journal Of Urology 2005, 173: 295. DOI: 10.1016/s0022-5347(18)35244-3.
- Kim I, Eichel L, Chou D, Abdelshehid C, Ahlering M, McDougall E, Clayman R. 649: Comparison of Laparoscopic Microwave Thermotherapy, Cryotherapy, and Radiofrequency Ablation for Destruction of Experimental VX-2 Renal Tumors in Rabbits. Journal Of Urology 2005, 173: 177. DOI: 10.1016/s0022-5347(18)34889-4.
- Kim I, Kim M, Kim S. Transforming Growth Factor-β: Biology and Clinical Relevance. BMB Reports 2005, 38: 1-8. PMID: 15715939, DOI: 10.5483/bmbrep.2005.38.1.001.
- Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research 2004, 64: 7355-7360. PMID: 15492256, DOI: 10.1158/0008-5472.can-04-0154.
- Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.
- Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.
- Shen S, Yu J, Kim I, Jian W, Matsumoto K, Kim M, Sonpavde G, Smith C, Ayala G, Younes M, Lerner S. 735: Differential Expression of Estrogen Receptor α and β in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue. Journal Of Urology 2004, 171: 195. DOI: 10.1016/s0022-5347(18)37984-9.
- Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. PMID: 14676131.
- Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.
- Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S. The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor-β Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*. Journal Of Biological Chemistry 2002, 277: 38557-38564. PMID: 12145312, DOI: 10.1074/jbc.m206786200.
- Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.
- Kim H, Kim B, Kim I, Mamura M, Do Hwan Seong, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.
- Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.
- Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.
- Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.
- KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION. Journal Of Urology 2001, 165: 903-904. DOI: 10.1097/00005392-200103000-00046.
- KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION. Journal Of Urology 2001, 165: 903-904. PMID: 11176503, DOI: 10.1016/s0022-5347(05)66561-5.
- Kim I, Schulam P. Laparoscopic nephrectomy for renal cell carcinoma. Current Urology Reports 2001, 2: 40-45. PMID: 12084294, DOI: 10.1007/s11934-001-0024-x.
- Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor. The Prostate 2000, 43: 118-124. PMID: 10754527, DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v.
- KIM I, SMITH C, OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS. Journal Of Urology 2000, 163: 237. DOI: 10.1097/00005392-200001000-00060.
- KIM I, SMITH C, OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS. Journal Of Urology 2000, 163: 237. PMID: 10604359, DOI: 10.1016/s0022-5347(05)68017-2.
- KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888.. DOI: 10.1097/00005392-199811000-00077.
- KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888. PMID: 9783979, DOI: 10.1016/s0022-5347(01)62437-6.
- Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. The Prostate 1998, 37: 51-59. PMID: 9721069, DOI: 10.1002/(sici)1097-0045(19980915)37:1<51::aid-pros8>3.0.co;2-b.
- Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. PMID: 9676836.
- Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.
- Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. PMID: 9533519.
- Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1. The Prostate 1997, 33: 64-71. PMID: 9294629, DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j.
- Yang S, Lee D, Hong S, Chung B, Kim I. Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonsei Medical Journal 1997, 38: 155-159. PMID: 9259615, DOI: 10.3349/ymj.1997.38.3.155.
- Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.
- Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.
- Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.
- Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Endocrinology 1996, 10: 107-15. PMID: 8838150, DOI: 10.1210/mend.10.1.8838150.
- Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.
- Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. PMID: 7530653, DOI: 10.1210/endo.136.2.7530653.
- Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. DOI: 10.1210/en.136.2.796.
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
- Yale UrologyOrchard Medical Center at St. Raphael’s Campus330 Orchard Street, Ste Suite 164New Haven, CT 06511
- Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830
- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519
- Yale UrologyOrchard Medical Center at St. Raphael’s Campus330 Orchard Street, Ste Suite 164New Haven, CT 06511
- Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830